The Link Between Parasitic Worms and Multiple Sclerosis

Parasitic worms and multiple sclerosis sit on opposite ends of an unlikely seesaw. Where helminth infections are common, MS rates tend to be low, and where modern sanitation has largely eliminated these parasites, autoimmune diseases like MS have surged. Over the past two decades, researchers have moved well beyond that geographic observation, tracking what happens inside the immune systems of MS patients who carry worm infections and even deliberately infecting volunteers with hookworms in clinical trials. The picture that emerges is complex, occasionally startling, and still far from a finished therapy.

Why Worms and Autoimmunity Keep Showing Up Together

The idea that reduced exposure to certain infections contributes to rising rates of autoimmune disease has been discussed in medicine for decades. Often called the hygiene hypothesis, and more recently refined as the “Old Friends” hypothesis, the core argument is straightforward: human immune systems evolved alongside organisms like parasitic worms over millions of years, and removing those organisms from the equation left our immune regulation incomplete. The Old Friends hypothesis specifically points to organisms that drove the development of regulatory immune cells, particularly regulatory T cells, which act as brakes on inflammatory responses.¹

MS is a condition in which the immune system attacks the myelin sheath protecting nerve fibers in the brain and spinal cord. It is most common in high-income countries at higher latitudes, places where parasite infections have become rare. In regions like Latin America, where helminth exposure remained more common into the modern era, researchers have noted that parasitic infections could be one factor keeping MS rates lower.² Strong epidemiological and experimental evidence now supports the broader principle that helminths and their byproducts play a protective role, and clinical trials have already been launched for MS, inflammatory bowel disease, rheumatoid arthritis, and type 1 diabetes.³

What Happened When MS Patients Were Already Infected

Some of the most compelling early evidence came not from deliberate experiments but from observational studies of MS patients who happened to pick up natural worm infections. A research team in Argentina followed MS patients over roughly four and a half years and compared those who carried intestinal parasites with those who did not. The results were striking: infected patients had significantly fewer relapses, minimal change in disability scores, and fewer new lesions visible on brain MRI scans.⁴

The same group then extended its follow-up to 90 months. Among the 12 MS patients carrying helminth infections, the disease stayed relatively quiet. But when four of those patients needed anti-parasite treatment because their worm-related symptoms became too severe, their MS roared back. Clearing the parasites was associated with a significant increase in both clinical relapses and new MRI activity.⁵ That before-and-after pattern within the same patients was particularly persuasive. It suggested the worms were not just a passive bystander but were actively dampening the autoimmune process, and that removing them reversed the benefit.

How Worms Dial Down the Immune System

Helminths are not subtle guests. They secrete a cocktail of molecules that reshape the immune environment around them, essentially reprogramming the host’s defenses to tolerate their presence. In doing so, they suppress the kinds of inflammatory responses that drive autoimmune damage.

In MS, the immune attack on myelin involves inflammatory T cells and the molecules they produce. Worm infections shift the immune balance away from that aggressive posture. During long-standing chronic infection, helminths suppress immune responses to unrelated targets, including the body’s own tissues, through the expansion of regulatory T cells and a shift toward a less inflammatory immune profile.⁶

The Argentine studies went further and identified a specific cellular player. MS patients who were carrying helminth infections developed a population of B cells that churned out high levels of interleukin-10, an anti-inflammatory signaling molecule. These regulatory B cells dampened harmful immune responses through a particular molecular pathway.⁷ So the worms were not simply turning down the whole immune system like a crude dial; they were selectively boosting the arm of immunity that acts as a peacekeeper.

Clinical Trials With Deliberate Infections

Observational studies can only take you so far. The real test is whether giving worms to MS patients on purpose produces measurable benefits. Two main approaches have been tried: infecting patients with hookworm larvae through the skin, and having them swallow eggs from a pig whipworm.

The Hookworm Trials

A randomized, double-blinded, placebo-controlled trial gave relapsing MS patients a small dose of the hookworm Necator americanus (applied as larvae to the skin) or a placebo. The main MRI outcome did not reach statistical significance by the study’s preplanned analysis, but the numbers leaned in a suggestive direction: about half of those in the hookworm group showed zero new MRI activity over the study period, compared with roughly a quarter in the placebo group. Relapses also trended lower, occurring in about 14% of the hookworm group versus about 31% of the placebo group.⁸ The trial was small, and the differences did not clear the conventional threshold for certainty, but the pattern was consistent with what the observational data had predicted.

Pig Whipworm Eggs

The other approach used Trichuris suis ova (TSO), eggs from a worm that infects pigs but cannot establish a lasting infection in humans. A phase 2 trial, known as HINT 2, found no serious adverse events. There was a trend consistent with about a 35% reduction in active brain lesions when comparing MRIs from before and during treatment, though this did not quite reach statistical significance either. Twelve of sixteen participants improved during the treatment period, and regulatory T cells increased.⁹ The immune changes mirrored what had been seen in naturally infected patients, lending biological plausibility even if the clinical numbers alone were not conclusive.

Neither trial delivered a slam-dunk result, and that has been the persistent frustration of this field. The signals keep pointing in the right direction, but the studies are too small and the effects too modest (against the backdrop of existing therapies) to transform clinical practice. Larger trials would be needed to confirm whether the hints are real.

What the Gut Has to Do With It

One of the more interesting side findings from the hookworm trial was what happened to participants’ gut bacteria. Researchers analyzed the gut microbiome of hookworm-treated and placebo-treated MS patients over the course of the trial. The placebo group experienced a significant decline in gut microbial diversity over time, a pattern that has been linked in other research to worsening autoimmune activity. The hookworm group, by contrast, maintained stable diversity.¹⁰

More specifically, a type of gut bacteria called Parabacteroides expanded significantly in hookworm-treated patients who had no clinical or MRI relapses by the end of the study. Parabacteroides species have been associated with anti-inflammatory functions in other research. The finding raises the possibility that worms do not only act through direct immune modulation; they may also reshape the microbial ecosystem of the gut in ways that independently protect against autoimmune flare-ups. This fits a broader understanding that parasites influence the gut-immune axis at multiple points, affecting intestinal barrier function and the signaling molecules gut bacteria produce.¹⁰

Evidence From Animal Models

Human trials are ethically and logistically complicated when the treatment involves a live parasite. Animal studies have filled in some important gaps, particularly around timing and mechanism. In the standard mouse model used to study MS, known as experimental autoimmune encephalomyelitis (EAE), helminth products have shown striking effects. One study found that excretory/secretory products from a tapeworm suppressed EAE with more potency than dexamethasone, a conventional anti-inflammatory steroid. The treatment worked even when given after symptoms had already started, suppressed inflammatory immune responses, promoted anti-inflammatory pathways, and reduced immune cell infiltration into the central nervous system.¹¹

That last detail matters a great deal. MS damage occurs when immune cells cross the blood-brain barrier and attack nerve tissue. If worm-derived substances can reduce that traffic without live infection, you have something closer to a conventional drug. Across different labs, roughly 20 studies using the EAE mouse model have reported that helminth infections or helminth-derived molecules reduce disease severity, making this one of the more consistently reproduced findings in experimental neuroimmunology.¹²

From Live Worms Toward Synthetic Molecules

The long-term vision in this field is not to prescribe parasites. Convincing regulators to approve a live infectious organism as a treatment for anything is extraordinarily difficult, and getting patients to accept it is another hurdle entirely. The real goal is to identify which molecules the worms secrete, figure out which ones are doing the heavy immunological lifting, and then produce those molecules synthetically or as recombinant proteins that could be tested as drugs.

Progress on this front has been steady if slow. Researchers have characterized more than 20 helminth proteins with immunomodulatory properties and developed recombinant versions of many of them, testing their effects in animal models of asthma and inflammatory bowel disease among other conditions.¹³ The broader field of helminth-derived immunotherapy is actively cataloguing excretory/secretory products that could serve as starting points for drug development.¹⁴

One recent example points toward how specific these molecules can become. A small peptide isolated from Schistosoma japonicum eggs was shown to arrest immune-activating cells in an immature state and boost the proportion and suppressive capacity of regulatory T cells.¹⁵ A single defined peptide, with a known target and a measurable immune effect, is a much more attractive starting point for drug development than a living hookworm burrowing through your intestine.

Why People Should Not Self-Treat

Despite the promising research, a small but persistent community of people has taken matters into their own hands, purchasing helminth larvae from unregulated suppliers and self-infecting. The risks here are real and distinct from what happens in a clinical trial. Trial participants receive carefully dosed, laboratory-raised organisms under medical supervision, with regular blood tests and imaging. Self-treaters are working blind: the dose is uncertain, the species may not be what is advertised, and there is no monitoring for complications.

Helminth infections are, after all, diseases. They can cause anemia, malnutrition, abdominal pain, intestinal obstruction, and organ damage depending on the species and the worm burden. The Argentine observational studies themselves demonstrated this tension. Four patients had to be treated for their worm infections because the parasitic symptoms became unacceptable, and doing so triggered MS relapses.⁵ The therapeutic window between “enough worms to modulate immunity” and “so many worms that you are sick from the infection” is not well defined, and it almost certainly varies from person to person.

There is also the issue of what worms do to the nervous system in ways unrelated to immune modulation. Parasites can trigger sustained inflammatory signaling in the periphery, disrupt gut barrier function, alter neurotransmitter metabolism, and in some cases directly affect the blood-brain barrier and brain cell function.¹⁶ The immune calming that benefits MS is just one channel of a much broader biological interaction between parasite and host, and not all of those channels are benign.

Where the Field Stands Now

The evidence linking parasitic worms to MS protection spans epidemiological patterns, natural-history observations in infected patients, controlled human trials, animal experiments, and molecular identification of active compounds. Each layer tells a consistent story: helminths modulate the immune system in ways that reduce the autoimmune attack on myelin. But none of the human trials conducted so far has been large enough, or has produced results definitive enough, to change how MS is treated in practice.

Part of the difficulty is practical. Modern MS drugs, while imperfect and often carrying their own serious side effects, have become quite effective at suppressing relapses. Running a trial large enough to show that a helminth intervention adds something on top of those therapies, or is equivalent to them, requires substantial funding and infrastructure. Another part is conceptual: a live parasite is not a pill, and the regulatory pathway for approving one as a therapeutic agent does not neatly exist. The pivot toward isolated worm-derived molecules may eventually solve that problem, but those molecules are still in early-stage testing.

For people living with MS today, the research offers no immediately actionable therapy. What it does offer is a genuinely fascinating window into how the immune system works and what goes wrong when it loses the evolutionary counterweights it was built to accommodate. The worms are not the treatment, at least not yet. But understanding what they do to our immune systems may be the key to designing one.

Implications for Other Autoimmune Diseases

MS is not the only autoimmune condition where helminth research has gained traction. The same immunological mechanisms that calm myelin-directed inflammation also suppress other misdirected immune responses. Clinical trials of helminth therapy have been conducted or are underway for inflammatory bowel disease, rheumatoid arthritis, and type 1 diabetes.³ The regulatory T cells and anti-inflammatory B cells that worms induce are not tissue-specific; they suppress inflammation broadly, which is why a gut parasite can affect what happens in the brain.

This generality is both promising and challenging. Promising because it suggests a single class of molecules could treat multiple conditions. Challenging because broadly suppressing inflammation is exactly what makes powerful immunosuppressive drugs dangerous: you risk leaving the patient vulnerable to infections and cancers. The hope with helminth-derived therapies is that they train the immune system to be more selective in its tolerance, rather than simply turning down the volume on everything. Whether that nuance can be captured in a pill remains the central open question of the field.